Facts About Barrett’s Esophagus
Here’s a list of notable information about Barrett’s Esophagus and Gastroesophageal Reflux Disease (GERD):
- Barrett’s Esophagus is a complication of Gastroesophageal Reflux Disease (GERD).
- Barrett’s Esophagus is considered a precursor to esophageal adenocarcinoma.
- GERD affects an estimated 25%-35% of the US population (7%-10% with daily symptoms).
- 10%-20% of patients with chronic GERD symptoms have Barrett’s Esophagus.
- 44% of Barrett’s patients lack consistent severe GERD symptoms.
- Barrett’s Esophagus patients have 30-125 times greater risk of developing esophageal cancer.
- The incidence of esophageal adenocarcinoma is rising more rapidly than any other cancer, six fold increase from 1975 to 2001.
- The prevalence of Barrett’s Esophagus in general population is 1.6%, approximately 3.3 million in the United States.
- In an endoscopic series of patients, 0.9%-4.5% had Barrett’s Esophagus. The prevalence of cancer, high grade dysplasia, and low grade dysplasia in Barrett’s Esophagus are 6.7%, 3.0%, and 7.3%, respectively.
- The incidence rate of cancer, high grade dysplasia, and low grade dysplasia in Barrett’s Esophagus are 0.5%, 0.9% and 4.3% per year, respectively.
- 5% of patients with Barrett’s Esophagus develop esophageal cancer within 5-8 years of diagnosis.
- The incidence of high grade dysplasia progressing to cancer is 10% (range 6%-19%) per year.
- The incidence of low grade dysplasia progressing to cancer is 0.6% per year.
- 53% of patients with cancer/high grade dysplasia have no dysplasia at their frist two scopes.
- Short segment Barrett’s (≤ 3 cm) is 3 times more common than long segment Barrett’s Esophagus.
- Genetic variation in two chromosomes have been linked to development of Barrett’s Esophagus.
- Risk of mortality from esophagectomy for Barrett’s Esophagus is 2% (range of 0-4%).
- Five year survival rate for late stage esophageal adenocarcinoma is approximately 13%.